BirkelandPHansenVTharmabalanV, et al. Long-term stroke risk in Moyamoya disease. Int J Stroke2024; 19: 452–459.
2.
RifinoNHervèDAcerbiF, et al. Diagnosis and management of adult Moyamoya angiopathy: an overview of guideline recommendations and identification of future research directions. Int J Stroke2025; 20: 512–523.
3.
WangJBernhardtJJohnsH, et al. An exploration of serious falls after stroke using a large international stroke rehabilitation database. Int J Stroke2025; 20: 550–558.
4.
MeadGGrahamCLundströmE, et al. Individual patient data meta-analysis of the effects of fluoxetine on functional outcomes after acute stroke. Int J Stroke2024; 19: 798–808.
5.
BroomfieldNMBlakeJGraceyFSteversonT.Post-stroke emotionalism: diagnosis, pathophysiology, and treatment. Int J Stroke2024; 19: 857–866.
6.
TayJ, EFFECTS Trial Collaboration, MårtenssonBMarkusHSLundströmE.Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the efficacy of fluoxetine—a randomized controlled trial in stroke trial data set. Int J Stroke2023; 18: 285–295.
7.
CholletFTardyJAlbucherJF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol2011; 10: 123–130.
8.
MeadGGrahamCLundströmE, et al. Fluoxetine and fractures after stroke: an individual patient data meta-analysis of three large randomized controlled trials of fluoxetine for stroke recovery. Int J Stroke2025; 20: 540–549.
9.
PollockASt GeorgeBFentonMFirkinsL.Top 10 research priorities relating to life after stroke—consensus from stroke survivors, caregivers, and health professionals. Int J Stroke2014; 9: 313–320.
10.
MokVCTCaiYMarkusHS.Vascular cognitive impairment and dementia: mechanisms, treatment, and future directions. Int J Stroke2024; 19: 838–856.
11.
KimTJLeeJSOhMS, et al. Risk of long-term post-stroke dementia using a linked dataset of patients with ischemic stroke without a history of dementia. Int J Stroke, 2025; 20: 601–610.
12.
SouthKMcCullochLMcCollBWElkindMSAllanSMSmithCJ.Preceding infection and risk of stroke: an old concept revived by the COVID-19 pandemic. Int J Stroke2020; 15: 722–732.
13.
LamichhaneBMawadAMMSalehM, et al. Salmonellosis: an overview of epidemiology, pathogenesis, and innovative approaches to mitigate the antimicrobial resistant infections. Antibiotics2024; 13: 76.
14.
ChenSSLinTTChiangYLChenCYLinWJChangR.Nontyphoidal salmonellosis is associated with an increased risk of stroke: insights from multinational real-world data. Int J Stroke2025; 20: 559–571.
15.
FeiginVLBraininMNorrvingB, et al. World Stroke Organization: global stroke fact sheet 2025. Int J Stroke2025; 20: 132–144.
